Literature DB >> 33020896

Age of onset and behavioral manifestations in Huntington's disease: An Enroll-HD cohort analysis.

Megha Ranganathan1,2, Sandra K Kostyk3, Dawn C Allain1, Jonathan A Race4,5, Allison M Daley3.   

Abstract

Huntington's disease is associated with motor, cognitive and behavioral dysfunction. Behavioral symptoms may present before, after, or simultaneously with clinical disease manifestation. The relationship between age of onset and behavioral symptom presentation and severity was explored using the Enroll-HD database. Manifest individuals (n = 4469) were initially divided into three groups for preliminary analysis: early onset (<30 years; n = 479); mid-adult onset (30-59 years; n = 3478); and late onset (>59 years; n = 512). Incidence of behavioral symptoms reported at onset was highest in those with early onset symptoms at 26% (n = 126), compared with 19% (n = 678) for mid-adult onset and 11% (n = 56) for late onset (P < 0.0001). Refined analysis, looking across the continuum of ages rather than between categorical subgroups found that a one-year increase in age of onset was associated with a 5.6% decrease in the odds of behavioral symptoms being retrospectively reported as the presenting symptom (P < 0.0001). By the time of study enrollment, the odds of reporting severe behavioral symptoms decreased by 5.5% for each one-year increase in reported age of onset. Exploring environmental, genetic and epigenetic factors that affect age of onset and further characterizing types and severity of behavioral symptoms may improve treatment and understanding of Huntington's disease's impact on affected individuals.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Huntington's disease; age of onset; behavior; phenotype

Year:  2020        PMID: 33020896     DOI: 10.1111/cge.13857

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  4 in total

1.  Brain, cognitive, and physical disability correlates of decreased quality of life in patients with Huntington's disease.

Authors:  Estefanía Junca; Mariana Pino; Hernando Santamaría-García; Sandra Baez
Journal:  Qual Life Res       Date:  2022-08-17       Impact factor: 3.440

2.  Translating cell therapies for neurodegenerative diseases: Huntington's disease as a model disorder.

Authors:  Anne E Rosser; Monica E Busse; William P Gray; Romina Aron Badin; Anselme L Perrier; Vicki Wheelock; Emanuele Cozzi; Unai Perpiña Martin; Cristina Salado-Manzano; Laura J Mills; Cheney Drew; Steven A Goldman; Josep M Canals; Leslie M Thompson
Journal:  Brain       Date:  2022-06-03       Impact factor: 15.255

Review 3.  Disordered Decision Making: A Cognitive Framework for Apathy and Impulsivity in Huntington's Disease.

Authors:  Lee-Anne Morris; Claire O'Callaghan; Campbell Le Heron
Journal:  Mov Disord       Date:  2022-05-02       Impact factor: 9.698

4.  Clinical and genetic characteristics of late-onset Huntington's disease in a large European cohort.

Authors:  Martina Petracca; Sonia Di Tella; Marcella Solito; Paola Zinzi; Maria Rita Lo Monaco; Giulia Di Lazzaro; Paolo Calabresi; Maria Caterina Silveri; Anna Rita Bentivoglio
Journal:  Eur J Neurol       Date:  2022-04-17       Impact factor: 6.288

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.